Advertisement

Pharmacokinetics Comparison, Intestinal Absorption and Acute Toxicity Assessment of a Novel Water-Soluble Astragaloside IV Derivative (Astragalosidic Acid, LS-102)

  • Lin-Sen Qing
  • Ting-Bo Chen
  • Wen-Xia Sun
  • Li Chen
  • Pei Luo
  • Zhi-Feng Zhang
  • Li-Sheng Ding
Original Research Article

Abstract

Background and Objectives

Astragaloside IV (AGS IV) is the most important bioactive constituent of Radix Astragali. However, its disappointing clinical application is mainly caused by its very low solubility in biologic fluids, resulting in poor bioavailability after oral administration. We recently obtained a novel water-soluble derivative of AGS IV (astragalosidic acid, LS-102) that displayed significant cardioprotective potential against hypoxia-induced injury. The objective of this study was to investigate the intestinal absorption, main pharmacokinetic parameters and acute toxicity of LS-102 in rodents compared with AGS IV.

Methods

An oral dose of LS-102 and AGS IV (20 mg/kg) was administered to Sprague-Dawley (SD) rats, and blood samples were collected at predetermined time points. The plasma concentrations were detected by a validated UHPLC-MS/MS method, and pharmacokinetic parameters were calculated using a compartmental model. In the intestinal permeability study, the transport of LS-102 across Caco-2 cell monolayers was investigated at six concentrations from 6.25 to 250 µM. Moreover, the acute toxicity of LS-102 (40–5000 mg/kg) via a single oral administration was investigated in BALB/c mice.

Results

LS-102 was rapidly absorbed, attaining a maximum concentration of 248.7 ± 22.0 ng/ml at 1.0 ± 0.5  h after oral administration. The relative bioavailability of LS-102 was twice that of AGS IV. LS-102 had a Papp (mean) of 15.72–25.50 × 10−6 cm/s, which was almost 500-fold higher than that of AGS IV, showing that LS-102 had better transepithelial permeability and could be better absorbed in the intestinal tract. The acute toxicity study showed no abnormal changes or mortality in mice treated with LS-102 even at the single high dose of 5000 mg/kg body weight.

Conclusions

Oral LS-102 produced a pharmacokinetic profile different from AGS IV with higher bioavailability, while the toxic tolerance was similar to previous estimates. Thus, we speculated that LS-102 might provide better clinical efficacy and be a potential candidate for the new drug development of Radix Astragali.

Notes

Compliance with Ethical Standards

Funding

This work was supported by the Chinese Academy of Sciences (CAS) ‘Light of West China’ Program and the Platform of Discovery, Evaluation and Transformation of Active Natural Compounds, Biological Resources Network, CAS.

Conflict of interest

The authors Lin-Sen Qing, Ting-bo Chen, Wen-Xia Sun, Li Chen, Pei Luo, Zhi-Feng Zhang and Li-Sheng Ding have no conflict of interest to declare.

Ethical approval

All animal experiments were carried out in accordance with the Institutional Guidelines and Animal Ordinance (Department of Health, Hong Kong Special Administrative Region) and approved by the Animal Ethics Committee of Macau University of Science and Technology (Macau Special Administrative Region).

References

  1. 1.
    Fu J, Wang Z, Huang L, Zheng S, et al. Review of the botanical characteristics, phytochemistry, and pharmacology of Astragalus membranaceus (Huangqi). Phytother Res. 2014;28(9):1275–83.  https://doi.org/10.1002/ptr.5188.CrossRefPubMedGoogle Scholar
  2. 2.
    Liao H, Hu L, Cheng X, Wang X, et al. Are the therapeutic effects of Huangqi (Astragalus membranaceus) on diabetic nephropathy correlated with its regulation of macrophage iNOS activity? J Immunol Res. 2017.  https://doi.org/10.1155/2017/3780572.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Wang K, Wu J, Duan X, Wu J, et al. Huangqi injection in the treatment of chronic heart failure: a systematic review and meta-analysis. Medicine. 2017;96(39):e8167.  https://doi.org/10.1097/MD.0000000000008167.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Wu L, Chen Y, Xu Y, Guo X, et al. Oral Huangqi formulae for stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. Evid-Based Compl Alt Med. 2013.  https://doi.org/10.1155/2013/705315.CrossRefGoogle Scholar
  5. 5.
    Yu L, Zhou C, Luo Z, Zeng W, et al. The lipid-lowering effects of Danhong and Huangqi injections: a meta-analysis of clinical controlled trials. Lipids Health Dis. 2018;17(1):106.  https://doi.org/10.1186/s12944-018-0760-2.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Li L, Hou X, Xu R, Liu C, et al. Research review on the pharmacological effects of astragaloside IV. Funda Clin Pharmacol. 2017;31(1):17–36.  https://doi.org/10.1111/fcp.12232.CrossRefGoogle Scholar
  7. 7.
    Xu M, Yin J, Xie L, Zhang J, et al. Pharmacokinetics and tolerance of toal astragalosides after intravenous infusion of astragalosides injection in healthy Chinese volunteers. Phytomedicine. 2013;20(12):1105–11.  https://doi.org/10.1016/j.phymed.2013.05.004.CrossRefPubMedGoogle Scholar
  8. 8.
    Xie J, Xiong J, Ding L-S, et al. A efficient method to identify cardioprotective components of Astragali Radix using a combination of molecularly imprinted polymers-based knockout extract and activity evaluation. J Chromatogr A. 2018.  https://doi.org/10.1016/j.chroma.2018.09.027.CrossRefPubMedGoogle Scholar
  9. 9.
    Du Y, Zhang Q, Chen G, et al. Pharmacokinetics of astragaloside IV in rats by liquid chromatography coupled with tandem mass spectrometry. Eur J Drug Metab Ph. 2005;30(4):269–73.  https://doi.org/10.1007/BF03190631.CrossRefGoogle Scholar
  10. 10.
    Gu Y, Wang G, Pan G, et al. Transport and bioavailability studies of astragaloside IV, an active ingredient in Radix Astragali. Basic Clin Pharmacol Toxicol. 2004;95(6):295–8.  https://doi.org/10.1111/j.1742-7843.2004.t01-1-pto950508.x.CrossRefPubMedGoogle Scholar
  11. 11.
    Zhang Q, Zhu L-L, Chen G-G, et al. Pharmacokinetics of astragaloside IV in beagle dogs. Eur J Drug Metab Ph. 2007;32(2):75–9.  https://doi.org/10.1007/BF03190995.CrossRefGoogle Scholar
  12. 12.
    Huang CR, Wang GJ, Wu XL, et al. Absorption enhancement study of astragaloside IV based on its transport mechanism in Caco-2 cells. Eur J Drug Metab Ph. 2006;31(1):5–10.  https://doi.org/10.1007/BF03190635.CrossRefGoogle Scholar
  13. 13.
    Lin J, Li C, Ruan L, et al. Study on the bioavailability of HP-β-cyclodextrin inclusion compound astragaloside IV in rats. China Pharmacist. 2010;13(4):469–71.Google Scholar
  14. 14.
    Liu A-N, Chen H, Tang X. Preparation and physical stability of astragaloside IV lipid microspheres for injection. Chin J Pharm. 2009;7(4):290–8.Google Scholar
  15. 15.
    Wang Y, Gao W. Study on solubilization effect of hydroxypropyl-β-cyclodextrin on astragaloside IV by phase solubility method. Chin Tradit Herb Drugs. 2007;38(5):710–1.Google Scholar
  16. 16.
    Qing L-S, Peng S-L, Liang J, et al. Astragalosidic acid: a new water-soluble derivative of astragaloside IV prepared using remarkably simple TEMPO-mediated oxidation. Molecules. 2017;22(8):1275.  https://doi.org/10.3390/molecules22081275.CrossRefGoogle Scholar
  17. 17.
    Gu Y, Wang G, Fawcett JP. Determination of astragaloside IV in rat plasma by liquid chromatography electrospray ionization mass spectrometry. J Chromatogr B. 2004;801(2):285–8.  https://doi.org/10.1016/j.jchromb.2003.11.033.CrossRefGoogle Scholar
  18. 18.
    Yan L-X, Guo D-A. Quantitation of astragaloside IV in rat plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B. 2005;824(1):244–8.  https://doi.org/10.1016/j.jchromb.2005.07.032.CrossRefGoogle Scholar
  19. 19.
    Zhang W, Zhang C, Liu R, et al. Quantitative determination of astragaloside IV, a natural product with cardioprotective activity, in plasma, urine and other biological samples by HPLC coupled with tandem mass spectrometry. J Chromatogr B. 2005;822(1):170–7.  https://doi.org/10.1016/j.jchromb.2005.05.034.CrossRefGoogle Scholar
  20. 20.
    Zhang W-D, Zhang C, Liu R-H, et al. Preclinical pharmacokinetics and tissue distribution of a natural cardioprotective agent astragaloside IV in rats and dogs. Life Sci. 2006;79(8):808–15.  https://doi.org/10.1016/j.lfs.2006.02.032.CrossRefPubMedGoogle Scholar
  21. 21.
    Hodin S, Basset T, Jacqueroux E, Delezay O, Clotagatide A, Perek N, Mismetti P, Delavenne X. In vitro comparison of the role of P-glycoprotein and breast cancer resistance protein on direct oral anticoagulants disposition. Eur J Drug Metab Pharmacokinet. 2018;43(2):183–91.  https://doi.org/10.1007/s13318-017-0434-x.CrossRefPubMedGoogle Scholar
  22. 22.
    Yang C-P, Li Z, Zhang T-H, Liu F, Ruan J-X, Zhang Z-Q. Transcellular transport of aconitine across human intestinal Caco-2 cells. Food Chem Toxicol. 2013;57:195–200.  https://doi.org/10.1016/j.fct.2013.03.033.CrossRefPubMedGoogle Scholar
  23. 23.
    Alexander B, Bonneau PR, Oliver H, Araz J, Edwards PJ. Development of specific “drug like property” rules for carboxylate containing oral drug candidates. ChemMedChem. 2010;5(12):2102–13.  https://doi.org/10.1002/cmdc.201000355.CrossRefGoogle Scholar
  24. 24.
    Jia Z-C, Li Y, Zhang L-S. The study of acute toxicity and mutagenicity of astragaloside. Mod Prev Med. 2013;40(6):1032–4.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Lin-Sen Qing
    • 1
  • Ting-Bo Chen
    • 2
  • Wen-Xia Sun
    • 3
  • Li Chen
    • 2
  • Pei Luo
    • 2
  • Zhi-Feng Zhang
    • 2
  • Li-Sheng Ding
    • 1
  1. 1.Chengdu Institute of Biology, Chinese Academy of SciencesChengduChina
  2. 2.State Key Laboratory for Quality Research of Chinese MedicinesMacau University of Science and TechnologyTaipaChina
  3. 3.Antibiotics Research and Re-evaluation Key Laboratory of Sichuan Province, Sichuan Industrial Institute of AntibioticsChengdu UniversityChengduChina

Personalised recommendations